The first Latin America Psychiatry Symposium organized by Luye Pharma (International) was successfully held on August 25, 2021, with the online symposium open to psychiatrists and healthcare professionals from both Latin America and North America. Over 370 participants from Brazil, Mexico, Argentina, the United States, and Central American countries attended the event. 

Three top local KOLs were invited to serve as the chair and lecturers at the symposium: Professor Helio Elkis from the University of Sao Paulo, Brazil, Professor Luis Alviso from Anahuac University, Mexico, and Professor Douglas Louis Noordsy from Stanford University, U.S.A. 

The meeting addressed hot topics and cutting-edge issues in the fields of the central nervous system (CNS) and psychiatry, including clinical use of antipsychotics in managing bipolar disorder and the relationship between lifestyle and brain recovery in patients with schizophrenia. During a discussion session after the lectures, panelists exchanged views on the difficulties and challenges in the clinical treatment of bipolar disorder and schizophrenia, triggering active participation and a lively discussion among physicians in attendance.   

Prior to this event, Luye Pharma (International) has organized three successful psychiatry symposiums in Asia Pacific, attracting thousands of psychiatrists and healthcare professionals from 10 different countries and regions. Luye Pharma (International) strives to create an academic brand with a forward looking, practical, and innovative approach to mental healthcare. The psychiatry symposiums are designed to provide a specialized platform for psychiatrists to address the hottest topics in the fields of mental illness research and clinical practice. 

Zhou Jun, Vice President of Marketing at Luye Pharma (International), said:

"I'm very excited to see that building on its past success, our academic brand is extending its coverage from Asia Pacific to the Americas, especially Latin America. We hope to continue to drive academic exchange in the CNS therapeutic field for psychiatric professionals in more countries and regions around the world, and look forward to working further with experts and academics in this area to drive the development of clinical treatment for CNS disorders." 

Luye Pharma has long been active in the CNS therapeutic area. In addition to offering high-quality and innovative drugs, the company is also committed to providing professional support and services to physicians and patients